# A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

> **NCT07000123** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 3103 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** AZD0780
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07000123
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-28
- **Primary completion:** 2027-01-11
- **Final completion:** 2027-01-11
- **Target enrollment:** 3103 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07000123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07000123, "A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT07000123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*